- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Vaccinex, Inc.: Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 13.05. | AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets | 230 | ACCESS Newswire | AbTherx and Single Cell Technology incorporate ActivMAb® Technology into Atlas Mouse and AbTheneum antibody discovery platforms MOUNTAIN VIEW, CA / ACCESS Newswire / May 13, 2025 / AbTherx, Inc., a... ► Artikel lesen | |
| 21.04. | Vaccinex berichtet: Pepinemab verstärkt Immunantwort bei Krebserkrankungen | 2 | Investing.com Deutsch | ||
| 21.04. | Vaccinex reports pepinemab boosts immune response in cancer | 1 | Investing.com | ||
| 21.04. | Vaccinex, Inc.: Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | 1 | GlobeNewswire (USA) | ||
| 15.04. | VACCINEX, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 01.04. | VACCINEX, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 2 | SEC Filings | ||
| 27.03. | VACCINEX, INC. - 15-12G, Securities registration termination | 2 | SEC Filings | ||
| VACCINEX Aktie jetzt für 0€ handeln | |||||
| 19.03. | VACCINEX, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | VACCINEX, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 10.03. | Vaccinex plans Nasdaq exit as Alzheimer market pressure grows | 3 | Pharmaceutical Technology | ||
| 07.03. | Vaccinex plans to delist common stock from Nasdaq | 1 | Seeking Alpha | ||
| 07.03. | Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market | 168 | GlobeNewswire (Europe) | ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating... ► Artikel lesen | |
| 07.03. | VACCINEX, INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.24 | Vaccinex receives delisting notice from Nasdaq, shares down over 49% | 3 | Seeking Alpha | ||
| 17.12.24 | Vaccinex wird aufgrund von Eigenkapitalmangel von der Nasdaq gestrichen | 4 | Investing.com Deutsch | ||
| 17.12.24 | Vaccinex to be delisted from Nasdaq over equity shortfall | 1 | Investing.com | ||
| 17.12.24 | Vaccinex, Inc.: Vaccinex Announces Receipt of Delisting Notification from Nasdaq | 162 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating... ► Artikel lesen | |
| 17.12.24 | VACCINEX, INC. - 8-K, Current Report | - | SEC Filings | ||
| 18.11.24 | Vaccinex, Inc.: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 205 | GlobeNewswire (Europe) | Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
| AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,524 | -0,38 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,437 | -2,02 % | NurExone stärkt US-Präsenz und bereitet klinische Studien vor | ||
| IBIO | 0,985 | +6,29 % | iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results | SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 14,850 | +0,75 % | Jim Cramer on Arrowhead Pharmaceuticals (ARWR): "It Doesn't Make Any Money" | ||
| COHERUS ONCOLOGY | 0,738 | +2,08 % | Coherus BioSciences, Inc. (CHRS): A Bull Case Theory | ||
| VOYAGER THERAPEUTICS | 3,174 | +2,59 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
| MEREO BIOPHARMA | 2,400 | -0,41 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights | Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 17,176 | +1,50 % | Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases | STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating... ► Artikel lesen | |
| BENITEC BIOPHARMA | 15,830 | +4,35 % | Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update | -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular... ► Artikel lesen | |
| CYBIN | 7,900 | +0,64 % | CYBIN INC. - 6-K, Report of foreign issuer |
Das Unternehmen VACCINEX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VACCINEX INC finden Sie auf Wallstreet Online.